Low body mass index and old age are useful in predicting the hemoglobin A1c-lowering effect of switching from sitagliptin to dulaglutide in Japanese patients with type 2 diabetes mellitus: a single-center, open-label, single-arm, pilot study.

Iwasaki T, Kessoku T, Higurashi T, Taguri M, Yoneda M

Diabetology international2 Feb 2018Cited by 3 (Europe PMC)

PMID30603366PMCIDPMC6224913DOI10.1007/s13340-018-0348-0PepBankPUB-30603366

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

3 results from studies that gave the peptide. 3 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with T2D, switching from sitagliptin to dulaglutide reduced fasting plasma glucose from baseline.
In plain wordsIn patients with T2D, switching from sitagliptin to dulaglutide reduced fasting blood glucose from baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseFasting plasma glucose
Study
n = 36
Comparator
Before switching from sitagliptin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg weekly · 24 weeksAs given in this study (human).
Source sentences
Summary
Dulaglutide administration for 24 weeks resulted in significant reductions in fasting plasma glucose (FPG), HbA1c, and low-density lipoprotein cholesterol (LDL-C) levels.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-center, open-label, investigator-initiated pilot study was conducted in 40 patients with type 2 diabetes mellitus. The patients, who had been treated with 50 mg sitagliptin daily for at least 6 months were switched to 0.75 mg dulaglutide weekly.
Report a problemFND-3060336601
02HumanNon-randomized trialEfficacy outcome
In patients with T2D, switching from sitagliptin to dulaglutide reduced HbA1c from baseline.
In plain wordsIn patients with T2D, switching from sitagliptin to dulaglutide reduced HbA1c from baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c
Study
n = 36
Comparator
Before switching from sitagliptin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg weekly · 24 weeksAs given in this study (human).
Source sentences
Summary
Dulaglutide administration for 24 weeks resulted in significant reductions in fasting plasma glucose (FPG), HbA1c, and low-density lipoprotein cholesterol (LDL-C) levels.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-center, open-label, investigator-initiated pilot study was conducted in 40 patients with type 2 diabetes mellitus. The patients, who had been treated with 50 mg sitagliptin daily for at least 6 months were switched to 0.75 mg dulaglutide weekly.
Report a problemFND-3060336602
03HumanNon-randomized trialEfficacy outcome
In patients with T2D, switching from sitagliptin to dulaglutide reduced LDL cholesterol from baseline.
In plain wordsIn patients with T2D, switching from sitagliptin to dulaglutide reduced LDL cholesterol from baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseLDL cholesterol
Study
n = 36
Comparator
Before switching from sitagliptin
Outcome group
Lipids · Metabolic and weight
Studied dose
0.75 mg weekly · 24 weeksAs given in this study (human).
Source sentences
Summary
Dulaglutide administration for 24 weeks resulted in significant reductions in fasting plasma glucose (FPG), HbA1c, and low-density lipoprotein cholesterol (LDL-C) levels.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-center, open-label, investigator-initiated pilot study was conducted in 40 patients with type 2 diabetes mellitus. The patients, who had been treated with 50 mg sitagliptin daily for at least 6 months were switched to 0.75 mg dulaglutide weekly.
Report a problemFND-3060336603

Studies that did not test the peptide alone4

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In patients with T2D who switched to dulaglutide, baseline HbA1c correlated with HbA1c change.
In plain wordsIn patients with T2D who switched to dulaglutide, baseline HbA1c was linked to HbA1c change.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedBaseline HbA1c association with HbA1c change
Study
n = 36
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
In addition, baseline HbA1c, FPG, body mass index (BMI), and age were significantly correlated with the change in HbA1c levels (ΔHbA1c).
1 context sentence(design, population, supporting numbers)
Summary · context
This single-center, open-label, investigator-initiated pilot study was conducted in 40 patients with type 2 diabetes mellitus. The patients, who had been treated with 50 mg sitagliptin daily for at least 6 months were switched to 0.75 mg dulaglutide weekly.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3060336604
05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In patients with T2D who switched to dulaglutide, baseline fasting plasma glucose correlated with HbA1c change.
In plain wordsIn patients with T2D who switched to dulaglutide, baseline fasting blood glucose was linked to HbA1c change.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedBaseline fasting glucose association with HbA1c change
Study
n = 36
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
In addition, baseline HbA1c, FPG, body mass index (BMI), and age were significantly correlated with the change in HbA1c levels (ΔHbA1c).
1 context sentence(design, population, supporting numbers)
Summary · context
This single-center, open-label, investigator-initiated pilot study was conducted in 40 patients with type 2 diabetes mellitus. The patients, who had been treated with 50 mg sitagliptin daily for at least 6 months were switched to 0.75 mg dulaglutide weekly.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3060336605
06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In patients with T2D who switched to dulaglutide, BMI correlated with HbA1c change, including in multiple linear regression.
In plain wordsIn patients with T2D who switched to dulaglutide, BMI was linked to HbA1c change, including in multiple linear regression.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedBMI association with HbA1c change
Study
n = 36
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
In addition, baseline HbA1c, FPG, body mass index (BMI), and age were significantly correlated with the change in HbA1c levels (ΔHbA1c). Furthermore, multiple linear regression analysis revealed that BMI and age significantly correlated with ΔHbA1c.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-center, open-label, investigator-initiated pilot study was conducted in 40 patients with type 2 diabetes mellitus. The patients, who had been treated with 50 mg sitagliptin daily for at least 6 months were switched to 0.75 mg dulaglutide weekly.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3060336606
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In patients with T2D who switched to dulaglutide, age correlated with HbA1c change, including in multiple linear regression.
In plain wordsIn patients with T2D who switched to dulaglutide, age was linked to HbA1c change, including in multiple linear regression.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedAge association with HbA1c change
Study
n = 36
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
In addition, baseline HbA1c, FPG, body mass index (BMI), and age were significantly correlated with the change in HbA1c levels (ΔHbA1c). Furthermore, multiple linear regression analysis revealed that BMI and age significantly correlated with ΔHbA1c.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-center, open-label, investigator-initiated pilot study was conducted in 40 patients with type 2 diabetes mellitus. The patients, who had been treated with 50 mg sitagliptin daily for at least 6 months were switched to 0.75 mg dulaglutide weekly.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3060336607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.